CTOs on the Move

NeuroVision Imaging

www.neurovision.com

 
NeuroVision is an integrated neuroscience company focused on delivering scientifically validated, diagnostic tests & biomarkers for early detection and monitoring of amyloid pathology related to Alzheimer’s Disease. The company has developed a novel retinal imaging technology, that is incorporated into a number of clinical trials globally.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

NeuroVision Imaging raised $11.2M on 05/02/2018

Similar Companies

GenPrime

GenPrime is a Spokane, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people`s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world`s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Bellerophon Therapeutics

Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases.

Nano Cures

The greatest health threats require more than an all-or-nothing approach. Nano represents a multi-layered set of solutions to usher in a new era in proactive, persistent health protection.

Rosetta Genomics

Founded in 2000, Rosetta's integrative research platform combining bioinformatics and state-of- the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs.   Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools and therapeutics.   Rosetta currently commercializes a full range of microRNA-based molecular diagnostics. Rosetta's cancer testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab.